The first CRISPR gene-editing drug, designed to treat blood disorders, could be on the market by 2023. Here’s what it means for the future of drug development.
The first CRISPR gene-editing drug, designed to treat blood disorders, could be on the market by 2023. Here’s what it means for the future of drug development.
Comments are closed.